The participant from the P-I/II dose-escalation, study dosed MGTA-117 at the Cohort 3 level (0.08 mg/kg) in r/r AML reported death and the company is working to evaluate the totality of available data and next steps for the development of MGTA-117
The death was reported due to Gr5 SAE (respiratory failure and cardiac arrest) that could be related to MGTA-117 and has been reported to the US FDA as a Suspected Unexpected Serious Adverse Reaction (SUSAR)
MGTA-117, an ADC targeting CD117 receptor and carrying an alpha-amanitin payload to kill cancer cells. It acts as a targeted conditioning therapeutic and reduces/eliminates the need for CT for patients receiving gene therapies or undergoing stem cell transplantation.
Ref: GlobeNewswire | Image: Magenta Therapeutics
Related News:- AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome
